The landscape of cancer treatment has witnessed a transformative shift with the advent of immunotherapies, notably the programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1) checkpoint blockade [1, 2]. The gene discussed is PDCD1; the disease is cancer.